secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001558370-23-014270
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte Q2 revenue down 6% YoY, core revenue down 14%; expects 2023 core revenue flat to 2022
--------------------------------------------------------------------------------

- Total revenue $9.0M in Q2 2023 (-6% YoY); core business revenue $8.3M (-14% YoY).
- Net loss $10.5M in Q2 vs $8.3M loss in Q2 2022; EBITDA loss $12.0M vs $8.2M.
- FY2023 guidance: core revenue now expected comparable to 2022 (flat); SPL program revenue unchanged ~$6M.
- Five SPL partnerships signed YTD including Lyell, ViTToria, Prime Medicine; total SPLs at 23.
- Cash and investments $216.1M as of June 30, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837023014270/0001558370-23-014270-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837023014270/mxct-20230809x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-014270

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer